% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • bohemianclubman bohemianclubman Mar 22, 2013 6:37 AM Flag


    Someone is always saying that Insmed doesn't have enough analyst coverage to own the shares.

    It's better to own the shares and then get the coverage. cannacord - 12 dollar target

    Others are always saying that getting a drug to market is and always will be a long, arduous, painstakng process. They are correct of course. However, the 2012 FDASIA, complete with QUIP and Breakthrough Designation is changing that:

    The best description of the pathway may have been delivered by Center for Drug Evaluation & Research Director Janet Woodcock during hearings on FDASIA: she said that the “breakthrough” designation would encourage the sponsor and the agency to call “all hands on deck” to rethink the development plan rather than plow through a traditional Phase 1-2-3 process.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
16.99+0.40(+2.41%)Nov 27 1:00 PMEST